- Home
- NIKI vs ERNA Comparison
NIKI vs ERNA Comparison
Compare NIKI & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIKI | ERNA |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.8M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NIKI | ERNA |
|---|---|---|
| Price | $8.93 | $3.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 27.9K | ★ 547.4K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $0.13 |
| 52 Week High | $8.82 | $15.88 |
Technical Indicators
Market Signals| Indicator | NIKI | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.85 |
| Support Level | N/A | $0.23 |
| Resistance Level | N/A | $7.94 |
| Average True Range (ATR) | 0.00 | 0.80 |
| MACD | 0.00 | -0.22 |
| Stochastic Oscillator | 0.00 | 2.22 |
Price Performance
Historical ComparisonAbout ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.